Inhaled insulin for the treatment of type 1 and type 2 diabetes

NICE technology appraisal guidance [TA113] Published date:

Important information about this appraisal

Important information about this appraisal

In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete.

Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications.

25 January 2008

Get involved